vimarsana.com

Latest Breaking News On - Boehringer ingelheim corporation - Page 4 : vimarsana.com

Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status

/PRNewswire/ Jardiance® (empagliflozin) reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and.

New yorkUnited statesStephan thalenFaiez zannadMohamed eidJennifer forsythEli lillyJeff emmickGlobal business communicationsBoehringer ingelheim pharmaceuticals incClinical development medical affairsBoehringer ingelheimBoehringer ingelheim animal health in duluthProduct developmentAssociation classUniversity of lorraine

Optina Diagnostics Closes an Oversubscribed Series-A Round of CA$24 8 million

This round was led by DigitalDx Ventures and supported by Boehringer Ingelheim Venture Fund Other investors include Desjardins Capital, Hike Ventures, Advisors.

United statesDavid lapointeDebbie linBoehringer ingelheim corporationDesjardins groupDigital health investmentsAdvisors fundBrain healthBoehringer ingelheim venture fundDigitaldx venturesDesjardins capitalHike venturesBiomed propulsionRetinal deepRetinal imagingSystemic disease

Optina Diagnostics Closes an Oversubscribed Series-A Round of CA$24 8 million

This round was led by DigitalDx Ventures and supported by Boehringer Ingelheim Venture Fund Other investors include Desjardins Capital, Hike Ventures, Advisors.

United statesDavid lapointeDebbie linBoehringer ingelheim corporationDesjardins groupDigital health investmentsAdvisors fundBrain healthBoehringer ingelheim venture fundDigitaldx venturesDesjardins capitalHike venturesBiomed propulsionRetinal deepRetinal imagingSystemic disease

U S FDA Approves Cyltezo® (adalimumab-adbm) as First Interchangeable Biosimilar with Humira®

/PRNewswire/ Boehringer Ingelheim today announced the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA).

United statesMartin alan menterThomas seckBoehringer ingelheim biopharmaRegulatory affairs at boehringer ingelheimAbbvie biotechnology ltdBoehringer ingelheim pharmaceuticals incBoehringer ingelheimDrug administrationBoehringer ingelheim animal health in duluthBoehringer ingelheim corporationAmerican academy of dermatologyAnimal healthBoehringer ingelheim fremont incBiologics license applicationRegulatory affairs

U S FDA Approves Cyltezo® (adalimumab-adbm) as First Interchangeable Biosimilar with Humira®

/PRNewswire/ Boehringer Ingelheim today announced the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA).

United statesMartin alan menterThomas seckBoehringer ingelheim biopharmaRegulatory affairs at boehringer ingelheimAbbvie biotechnology ltdBoehringer ingelheim pharmaceuticals incBoehringer ingelheimDrug administrationBoehringer ingelheim animal health in duluthBoehringer ingelheim corporationAmerican academy of dermatologyAnimal healthBoehringer ingelheim fremont incBiologics license applicationRegulatory affairs

vimarsana © 2020. All Rights Reserved.